DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer

Carcinogenesis

Volumn 31, Issue 11, 2010, Pages 1972-1976

  Wilhelm Benartzi, C S ^a   Koestler, D C ^a   Houseman, E A ^a   Christensen, B C ^a,b   Wiencke, John K ^c   Schned, A R ^d   Karagas, M R ^d   Kelsey, K T ^a   Marsit, C J ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; DNA; FORMALDEHYDE; PARAFFIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLADDER CANCER; CANCER GENETICS; CANCER INVASION; CANCER RISK; CONTROLLED STUDY; CPG ISLAND; DEMOGRAPHY; DNA METHYLATION; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE LOCUS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SEX DIFFERENCE; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEW HAMPSHIRE; PROGNOSIS; RISK FACTORS; SMOKING; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 78149277443     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq178     Document Type: Article

References (48)

1. Schilsky, R.L. (2010) Personalized medicine in oncology: the future is now. Nat. Rev. Drug Discov., 9, 363-366.
2. Genomic Health, Inc. (2010) Oncotype Dx Breast Cancer Assay Website. Genomic Health Inc, Redwood City, CA.
3. Wikman, H. et al. (2007) Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer. Oncogene, 26, 4730-4737.
4. Tan, M.H. et al. (2010) Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer, 10, 196.
5. American Cancer Society. (2009) Cancer Facts and Figures 2009. American Cancer Society, Atlanta, GA.
6. Kaufman, D.S. et al. (2009) Bladder cancer. Lancet, 374, 239-249.
7. Dinney, C.P. et al. (2004) Focus on bladder cancer. Cancer Cell, 6, 111-116.
8. Parkin, M.P. (2008) The global burden of urinary bladder cancer. Scand. J. Urol. Nephrol. Suppl., 42, 12-20.
9. Karagas, M.R. et al. (2004) Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire. Cancer Causes Control, 15, 465-472.
10. Boffetta, P. (2006) Human cancer from environmental pollutants: the epidemiological evidence. Mutat. Res., 608, 157-162.
11. Baylin, S.B. et al. (2006) Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction. Nat. Rev. Cancer, 6, 107-116.
12. Jones, P.A. et al. (2002) The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3, 415-428.
13. Wolff, E.M. et al. (2005) Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat. Clin. Pract. Urol., 2, 502-510.
14. Marsit, C.J. et al. (2006) Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis, 27, 112-116.
15. Marsit, C.J. et al. (2007) Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. Carcinogenesis, 28, 1745-1751.
16. Zhu, Y. et al. (2004) Methyl-CpG-binding domain 2: a protective role in bladder carcinoma. Cancer, 100, 1853-1858.
17. Malekzadeh, K. et al. (2009) Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer. Cancer Invest., 27, 70-80.
18. Marsit, C.J. et al. (2010) Identification of methylated genes associated with aggressive bladder cancer. PLoS One, 5, e12334.
19. Tao, M.H. et al. (2009) DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res. Treat., 114, 559-568.
20. Mokarram, P. et al. (2009) Distinct high-profile methylated genes in colorectal cancer. PLoS One, 4, e7012.
21. Marsit, C.J. et al. (2009) Epigenetic profiling reveals etiologically distinct patterns of DNA methylation in head and neck squamous cell carcinoma. Carcinogenesis, 30, 416-422.
22. Baris, D. et al. (2009) A case-control study of smoking and bladder cancer risk: emergent patterns over time. J. Natl Cancer Inst., 101, 1553-1561.
23. Karagas, M.R. et al. (1998) Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. Environ. Health. Perspect., 106, 1047-1050.
24. Wallace, K. et al. (2009) Selenium and risk of bladder cancer: a populationbased case-control study. Cancer Prev. Res. (Phila. Pa), 2, 70-73.
25. Meza, M.M. et al. (2005) Developmentally restricted genetic determinants of human arsenic metabolism: association between urinary methylated arsenic and CYT19 polymorphisms in children. Environ. Health. Perspect., 113, 775-781.
26. Kwong, R.C. et al. (2009) Arsenic exposure predicts bladder cancer survival in a US population. World J. Urol, 28, 487-492.
27. Karagas, M.R. et al. (2000) Measurement of low levels of arsenic exposure: a comparison of water and toenail concentrations. Am. J. Epidemiol., 152, 84-90.
28. Andrew, A.S. et al. (2009) DNA repair genotype interacts with arsenic exposure to increase bladder cancer risk. Toxicol. Lett., 187, 10-14.
29. Marsit, C.J. et al. (2005) Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res., 65, 7081-7085.
30. Bibikova, M. et al. (2006) High-throughput DNA methylation profiling using universal bead arrays. Genome Res., 16, 383-393.
31. Christensen, B.C. et al. (2010) Breast cancer DNA methylation profiles are associated with tumor size and alcohol and folate intake. PLoS Genet, 6, e1001043.
32. Bibikova, M. et al. (2009) GoldenGate assay for DNA methylation profiling. Methods Mol. Biol., 507, 149-163.
33. Wilhelm, C.S. et al. (2010) Implications of LINE1 methylation for bladder cancer risk in women. Clin. Cancer Res., 16, 1682-1689.
34. Sobti, R.C. et al. (2010) Hypermethylation-mediated partial transcriptional silencing of DAP-kinase gene in bladder cancer. Biomarkers, 15, 167-174.
35. Brait, M. et al. (2008) Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol. Biomarkers Prev., 17, 2786-2794.
36. Rossman, T.G. (2003) Mechanism of arsenic carcinogenesis: an integrated approach. Mutat. Res., 533, 37-65.
37. Zhao, C.Q. et al. (1997) Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl Acad. Sci. USA, 94, 10907-10912.
38. Zhong, C.X. et al. (2001) Both hypomethylation and hypermethylation of DNA associated with arsenite exposure in cultures of human cells identified by methylation-sensitive arbitrarily-primed PCR. Toxicol. Lett., 122, 223-234.
39. Mass, M.J. et al. (1997) Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat. Res., 386, 263-277.
40. Meliker, J.R. et al. (2010) Lifetime exposure to arsenic in drinking water and bladder cancer: a population-based case-control study in Michigan, USA. Cancer Causes Control, 21, 745-757.
41. Mink, P.J. et al. (2008) Low-level arsenic exposure in drinking water and bladder cancer: a review and meta-analysis. Regul. Toxicol. Pharmacol., 52, 299-310.
42. Puente, D. et al. (2003) Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer. Eur. Urol., 43, 53-62
43. Hartge, P. et al. (1990) Unexplained excess risk of bladder cancer in men. J. Natl Cancer Inst., 82, 1636-1640.
44. Radosavljević, V. et al. (2004) Non-occupational risk factors for bladder cancer: a case-control study. Tumori, 90, 175-180.
45. Michaud, D.S. et al. (1999) Fluid intake and the risk of bladder cancer in men. N. Engl. J. Med., 340, 1390-1397.
46. Villanueva, C.M. et al. (2006) Total and specific fluid consumption as determinants of bladder cancer risk. Int. J. Cancer., 118, 2040-2047.
47. Karagas, M.R. et al. (2002) Assessment of cancer risk and environmental levels of arsenic in New Hampshire. Int. J. Hyg. Environ. Health, 205, 85-
48. Karagas, M.R. et al. (2001) Markers of low level arsenic exposure for evaluating human cancer risks in a US population. Int. J. Occup. Med. Environ. Health, 14, 171-175.